Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for shares of Ardelyx in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter, down from their previous forecast of ($0.05). HC Wainwright currently has a "Neutral" rating and a $5.50 price target on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx's Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $1.06 EPS.
A number of other research firms have also commented on ARDX. Citigroup cut their price objective on Ardelyx from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Wedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Ardelyx in a research report on Friday, August 2nd. Finally, StockNews.com upgraded shares of Ardelyx from a "sell" rating to a "hold" rating in a report on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Ardelyx has a consensus rating of "Moderate Buy" and a consensus price target of $10.42.
Check Out Our Latest Analysis on Ardelyx
Ardelyx Stock Performance
Shares of NASDAQ ARDX traded down $0.09 during trading on Wednesday, reaching $4.50. The company had a trading volume of 4,828,415 shares, compared to its average volume of 4,954,597. The company's fifty day moving average price is $5.99 and its 200-day moving average price is $6.28. The company has a current ratio of 4.03, a quick ratio of 3.87 and a debt-to-equity ratio of 0.64. Ardelyx has a 12 month low of $3.82 and a 12 month high of $10.13.
Insider Transactions at Ardelyx
In other Ardelyx news, insider David P. Rosenbaum sold 27,171 shares of the company's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $6.10, for a total value of $165,743.10. Following the completion of the sale, the insider now directly owns 153,616 shares of the company's stock, valued at approximately $937,057.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Ardelyx news, insider David P. Rosenbaum sold 20,000 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $5.94, for a total transaction of $118,800.00. Following the completion of the transaction, the insider now directly owns 356,479 shares of the company's stock, valued at approximately $2,117,485.26. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David P. Rosenbaum sold 27,171 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $6.10, for a total value of $165,743.10. Following the completion of the sale, the insider now owns 153,616 shares in the company, valued at approximately $937,057.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 267,983 shares of company stock worth $1,632,802 in the last quarter. 5.90% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Ardelyx
Several large investors have recently added to or reduced their stakes in the company. Redmile Group LLC purchased a new stake in shares of Ardelyx during the first quarter worth $16,020,000. Millennium Management LLC lifted its holdings in Ardelyx by 142.8% during the 2nd quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company's stock worth $23,735,000 after purchasing an additional 1,883,995 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Ardelyx by 68.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company's stock worth $28,572,000 after purchasing an additional 1,584,597 shares during the period. Rubric Capital Management LP grew its holdings in Ardelyx by 68.5% during the 3rd quarter. Rubric Capital Management LP now owns 3,060,191 shares of the biopharmaceutical company's stock valued at $21,085,000 after buying an additional 1,243,606 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Ardelyx by 2.8% during the 1st quarter. Vanguard Group Inc. now owns 13,391,855 shares of the biopharmaceutical company's stock valued at $97,761,000 after buying an additional 365,809 shares in the last quarter. Hedge funds and other institutional investors own 58.92% of the company's stock.
Ardelyx Company Profile
(
Get Free Report)
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Featured Articles
Before you consider Ardelyx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.
While Ardelyx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.